Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BMP2 | P12643 | 1/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | SHH | Q15465 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 5/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
| ▸ | PTN | P21246 | 1/20 | 0.38 |
| ▸ | MDK | P21741 | 1/20 | 0.38 |
| ▸ | BDNF | P23560 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220660 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL19225475 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL19225495 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL19225477 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL19225429 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL19220669 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL25853180 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL22617797 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL20685511 | 1.00 | TLR4 (0.44) | TLR4MAPK1BMP2VEGFACXCL12 | |
| SCHEMBL23773084 | 0.95 | MAPK1 (0.47) | TLR4MAPK1BMP2VEGFACXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227770-A1 | Bacillus Isolates and Uses Thereof | NOVOZYMES BIOAG A/S (DK) | 2023-07-20 | — | — | US | disclosed |
| US-11560342-B2 | Bacillus isolates and uses thereof | MONSANTO TECHNOLOGY, LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210068401-A1 | BACILLUS ISOLATES AND USES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20190345572-A1 | LYSINIBACILLUS ISOLATES AND USES THEREOF | NOVOZYMES BIOAG A/S (DK) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345572-A1 | LYSINIBACILLUS ISOLATES AND USES THEREOF | GLB1, PGLS, LYPLAL1 | TLR4 2031/4885MAPK1 4144/4885BMP2 1886/4885 |
| US-20210068401-A1 | BACILLUS ISOLATES AND USES THEREOF | BLVRB, BROX, GLB1 | TLR4 770/4885MAPK1 3187/4885BMP2 486/4885 |
| US-11560342-B2 | Bacillus isolates and uses thereof | BLVRB, BROX, GLB1 | TLR4 770/4885MAPK1 3187/4885BMP2 486/4885 |
| US-20230227770-A1 | Bacillus Isolates and Uses Thereof | BLVRB, GLB1, SPOUT1 | TLR4 1168/4885MAPK1 3196/4885BMP2 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.